IN2014MN02418A - - Google Patents

Download PDF

Info

Publication number
IN2014MN02418A
IN2014MN02418A IN2418MUN2014A IN2014MN02418A IN 2014MN02418 A IN2014MN02418 A IN 2014MN02418A IN 2418MUN2014 A IN2418MUN2014 A IN 2418MUN2014A IN 2014MN02418 A IN2014MN02418 A IN 2014MN02418A
Authority
IN
India
Prior art keywords
methods
breast cancer
subject
gene expression
evaluating
Prior art date
Application number
Inventor
Sean M Ferree
James Justin Storhoff
Joel S Parker
Charles M Perou
Matthew J Ellis
Philip S Bernard
Torsten O Nielsen
Original Assignee
Nanostring Technologies Inc
Univ North Carolina
Univ Utah Res Found
British Columbia Cancer Agency
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanostring Technologies Inc, Univ North Carolina, Univ Utah Res Found, British Columbia Cancer Agency, Univ Washington filed Critical Nanostring Technologies Inc
Publication of IN2014MN02418A publication Critical patent/IN2014MN02418A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

The present invention provides methods for classifying and for evaluating the prognosis of a subject having breast cancer are provided. The methods include prediction of breast cancer subtype using a supervised algorithm trained to stratify subjects on the basis of breast cancer intrinsic subtype. The prediction model is based on the gene expression profile of the intrinsic genes listed in Table 1. Further provided are compositions and methods for predicting outcome or response to therapy of a subject diagnosed with or suspected of having breast cancer. These methods are useful for guiding or determining treatment options for a subject afflicted with breast cancer. Methods of the invention further include means for evaluating gene expression profiles including microarrays and quantitative polymerase chain reaction assays as well as kits comprising reagents for practicing the methods of the invention.
IN2418MUN2014 2012-05-22 2013-05-22 IN2014MN02418A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261650209P 2012-05-22 2012-05-22
US201361753673P 2013-01-17 2013-01-17
PCT/US2013/042157 WO2013177245A2 (en) 2012-05-22 2013-05-22 Nano46 genes and methods to predict breast cancer outcome

Publications (1)

Publication Number Publication Date
IN2014MN02418A true IN2014MN02418A (en) 2015-08-14

Family

ID=49624503

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2418MUN2014 IN2014MN02418A (en) 2012-05-22 2013-05-22

Country Status (12)

Country Link
US (3) US20130337444A1 (en)
EP (1) EP2852689B1 (en)
JP (1) JP6325530B2 (en)
CN (2) CN104704128A (en)
AU (1) AU2013266419B2 (en)
BR (1) BR112014029300A2 (en)
CA (1) CA2874492C (en)
ES (1) ES2763931T3 (en)
IL (1) IL235795B (en)
IN (1) IN2014MN02418A (en)
MX (1) MX369628B (en)
WO (1) WO2013177245A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2297359T3 (en) 2008-05-30 2014-02-24 Univ Utah Res Found Gene expression profiles to predict the outcome of breast cancer
JP5971769B2 (en) 2011-03-15 2016-08-17 ザ ユニバーシティー オブ ノースカロライナ アット チャペル ヒル Methods of treating breast cancer using anthracycline therapy
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
EP2785873A4 (en) 2011-11-30 2015-11-11 Univ North Carolina Methods of treating breast cancer with taxane therapy
WO2014186349A1 (en) * 2013-05-13 2014-11-20 Nanostring Technologies, Inc. Methods to predict risk of recurrence in node-positive early breast cancer
CN111662960B (en) 2013-06-25 2024-04-12 普罗格诺西斯生物科学公司 Spatially encoded bioanalytical analysis using microfluidic devices
JP2016537010A (en) 2013-09-09 2016-12-01 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ Method and kit for predicting prognosis, and method and kit for treating breast cancer using radiation therapy
KR102298387B1 (en) 2014-11-21 2021-09-07 나노스트링 테크놀로지스, 인크. Enzyme- and amplification-free sequencing
KR102602507B1 (en) * 2014-11-24 2023-11-14 나노스트링 테크놀로지스, 인크. Methods and apparatuses for gene purification and imaging
EP3230466A1 (en) * 2014-12-09 2017-10-18 King's College London Breast cancer treatment with taxane therapy
DK3901281T3 (en) 2015-04-10 2023-01-23 Spatial Transcriptomics Ab SPATIALLY SEPARATE, MULTIPLEX NUCLEIC ACID ANALYSIS OF BIOLOGICAL SAMPLES
CN107850599B (en) * 2015-07-23 2021-02-09 新加坡国立大学 Stratification of patients for treatment with WBP2 and HER2 as co-prognostic factors
CA3023566A1 (en) 2016-05-16 2017-11-23 Nanostring Technologies, Inc. Methods for detecting target nucleic acids in a sample
WO2017222453A1 (en) 2016-06-21 2017-12-28 Hauling Thomas Nucleic acid sequencing
WO2018074865A2 (en) * 2016-10-21 2018-04-26 서울대학교병원 Composition and method for breast cancer prognosis prediction
AU2017361521B2 (en) 2016-11-21 2020-08-27 Nanostring Technologies, Inc. Chemical compositions and methods of using same
KR101950717B1 (en) * 2016-11-23 2019-02-21 주식회사 젠큐릭스 Methods for predicting effectiveness of chemotherapy for breast cancer patients
WO2018144782A1 (en) * 2017-02-01 2018-08-09 The Translational Genomics Research Institute Methods of detecting somatic and germline variants in impure tumors
WO2019068880A1 (en) 2017-10-06 2019-04-11 Cartana Ab Rna templated ligation
KR102071491B1 (en) * 2017-11-10 2020-01-30 주식회사 디시젠 Breast cancer prognosis prediction method and system based on machine learning using next generation sequencing
SG11202011274YA (en) 2018-05-14 2020-12-30 Nanostring Technologies Inc Chemical compositions and methods of using same
WO2020094399A1 (en) * 2018-11-05 2020-05-14 Biontech Diagnostics Gmbh Predictive methods in breast cancer
AU2020282024A1 (en) 2019-05-31 2021-11-11 10X Genomics, Inc. Method of detecting target nucleic acid molecules
JP7352937B2 (en) * 2019-07-19 2023-09-29 公立大学法人福島県立医科大学 Differential marker gene set, method and kit for differentiating or classifying breast cancer subtypes
EP3945136A1 (en) * 2020-07-28 2022-02-02 Hospital Clínic de Barcelona In vitro method for the prognosis of patients suffering from her2-positive breast cancer
WO2023117807A1 (en) * 2021-12-20 2023-06-29 Reveal Genomics S.L Development and validation of an in vitro method for the prognosis of patients suffering from her2-positive breast cancer

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
AU669489B2 (en) 1991-09-18 1996-06-13 Affymax Technologies N.V. Method of synthesizing diverse collections of oligomers
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
DE69233331T3 (en) 1991-11-22 2007-08-30 Affymetrix, Inc., Santa Clara Combinatorial Polymersynthesis Strategies
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc Nucleic acid analysis techniques
AU1287799A (en) 1997-10-31 1999-05-24 Affymetrix, Inc. Expression profiles in adult and fetal organs
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6750015B2 (en) * 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
US20020168639A1 (en) * 2000-09-22 2002-11-14 Muraca Patrick J. Profile array substrates
CA3061769C (en) 2003-06-24 2021-10-26 Genomic Health, Inc. Methods of predicting the likelihood of long-term survival of a human patient with node-negative, estrogen receptor (er) positive, invasive ductal breast cancer without the recurrence of breast cancer
EP2469439A2 (en) * 2003-09-29 2012-06-27 Pathwork Diagnostics, Inc. Systems and methods for detecting biological features
CA2574447A1 (en) 2004-07-15 2006-01-26 University Of Utah Research Foundation Housekeeping genes and methods for identifying the same
CN101061480A (en) * 2004-09-22 2007-10-24 三路影像公司 Methods and computer program products for analysis and optimization of marker candidates for cancer prognosis
WO2007061876A2 (en) 2005-11-23 2007-05-31 University Of Utah Research Foundation Methods and compositions involving intrinsic genes
WO2007076132A2 (en) 2005-12-23 2007-07-05 Nanostring Technologies, Inc. Compositions comprising oriented, immobilized macromolecules and methods for their preparation
JP5537034B2 (en) 2005-12-23 2014-07-02 ナノストリング テクノロジーズ，インコーポレーテッド Nanoreporter and method for producing and using the same
WO2008124847A2 (en) 2007-04-10 2008-10-16 Nanostring Technologies, Inc. Methods and computer systems for identifying target-specific sequences for use in nanoreporters
WO2008150512A2 (en) * 2007-06-04 2008-12-11 University Of Louisville Research Foundation, Inc. Methods for identifying an increased likelihood of recurrence of breast cancer
CN102395682B (en) * 2007-09-06 2015-09-30 生物治疗诊断股份有限公司 Tumor grade and cancer prognosis
DK2297359T3 (en) 2008-05-30 2014-02-24 Univ Utah Res Found Gene expression profiles to predict the outcome of breast cancer
CA2733609C (en) 2008-08-14 2018-03-06 Nanostring Technologies, Inc. Stable nanoreporters
EP2553118B1 (en) * 2010-03-31 2014-10-15 Sividon Diagnostics GmbH Method for breast cancer recurrence prediction under endocrine treatment

Also Published As

Publication number Publication date
IL235795A0 (en) 2015-01-29
MX369628B (en) 2019-11-14
CA2874492C (en) 2021-10-19
BR112014029300A2 (en) 2017-07-25
JP2015518724A (en) 2015-07-06
CA2874492A1 (en) 2013-11-28
AU2013266419B2 (en) 2018-09-27
WO2013177245A2 (en) 2013-11-28
JP6325530B2 (en) 2018-05-16
MX2014014275A (en) 2015-07-06
EP2852689B1 (en) 2019-12-11
ES2763931T3 (en) 2020-06-01
EP2852689A4 (en) 2016-05-11
US20200332368A1 (en) 2020-10-22
CN104704128A (en) 2015-06-10
IL235795B (en) 2020-02-27
EP2852689A2 (en) 2015-04-01
CN111500718A (en) 2020-08-07
US20230272476A1 (en) 2023-08-31
AU2013266419A1 (en) 2014-12-11
WO2013177245A3 (en) 2015-01-29
US20130337444A1 (en) 2013-12-19

Similar Documents

Publication Publication Date Title
IN2014MN02418A (en)
CY1114993T1 (en) Gene Expression Profile To Predict Breast Cancer Outcomes
MX2019007814A (en) Gene expression profile algorithm and test for determining prognosis of prostate cancer.
MX2020001156A (en) Method for the prognosis and treatment of cancer metastasis.
MX2014006404A (en) Methods and kits for the prognosis of colorectal cancer.
EA201370063A1 (en) PHOSPHOLYPIDE CANCER
EP4219765A3 (en) Prostate cancer prognosis using biomarkers
NZ599194A (en) Methods to predict clinical outcome of cancer
WO2015052583A3 (en) Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer
MX357429B (en) Predictors for cancer treatment.
PH12014502410A1 (en) Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression
NZ621638A (en) Dna methylation in colorectal and breast cancer diagnostic methods
WO2011153545A3 (en) Gene expression signature as a predictor of chemotherapeutic response in breast cancer
WO2014184679A3 (en) Method for the prognosis and treatment of renal cell carcinoma metastasis
MX2013008252A (en) Prognostic signature for colorectal cancer recurrence.
BR112015022977A2 (en) methods for predicting risk of metastasis in cutaneous melanoma
Montserrat et al. Present and future of personalized medicine in CLL
IN2014DN08312A (en)
RU2010149541A (en) METHOD FOR FORECASTING THE DEVELOPMENT OF METABOLIC SYNDROME IN A PATIENT WITH ABDOMINAL OBESITY
RU2012140862A (en) METHOD FOR FORECASTING RISK OF RISK OF FRACTURES
UA108260U (en) METHOD OF FORECASTING OSTEOPOROSIS DEVELOPMENT
WO2011133500A3 (en) Detection and analysis of epigenetic and genetic changes in tumor tissue
UA95616U (en) METHOD OF FORECASTING FRAGMENT FRAGMENT
Brennan Quantifying Biomarker Risks and Benefits
Ellis Whole Genome Sequencing for Luminal-Type Breast Cancer